Literature DB >> 8096844

Transglutaminase-catalyzed incorporation of polyamines into phospholipase A2.

E Cordella-Miele1, L Miele, S Beninati, A B Mukherjee.   

Abstract

We have previously demonstrated that when phospholipase A2 is treated with either tissue transglutaminase or human plasma Factor XIIIa, a striking increase of its catalytic activity is observed, due to the formation of an intramolecular epsilon-(gamma-glutamyl)-lysine crosslink [Cordella-Miele et al. (1990) J. Biol. Chem. 265, 17180-17188]. Here, we report the effect of transglutaminase substrates such as mono-, di-, and polyamines on this transglutaminase-catalyzed post-translational modification of phospholipase A2. Incorporation of radioactively labeled polyamines into phospholipase A2 was demonstrated by using porcine pancreatic phospholipase A2 as a substrate in a conventional transglutaminase assay. These results were further confirmed by SDS-polyacrylamide gel electrophoresis followed by fluorography. Additionally, gamma-glutamyl-polyamine was detected and unequivocally identified in proteolytic digests of polyaminated phospholipase A2. When phospholipase A2 was incubated with transglutaminase in the presence of putrescine, spermine, spermidine, dansylcadaverine, or methylamine, a 2-3-fold increase in phospholipase A2 activity was observed. The increase of phospholipase A2 activity was found to be dependent upon the concentration of phospholipase A2, preincubation time, and the duration of the reaction. Increase in phospholipase A2 activity after transglutaminase treatment in the presence of polyamines was demonstrated using two different assay systems. Kinetic studies on phospholipase A2 pretreated with spermidine and transglutaminase demonstrated a significant increase of the apparent Vmax but no significant change in the apparent Km. Unlike phospholipase A2 pretreated with transglutaminase alone, polyaminated phospholipase A2 does not undergo non-covalent dimerization in solution. Polyaminated phospholipase A2 was further purified by chromatofocusing and was found to contain N-mono(gamma-glutamyl)-spermidine in a molar ratio of about 1:1 to phospholipase A2. Freshly purified, polyaminated phospholipase A2 had a specific activity approximately 3-fold higher than that of control phospholipase A2 treated in an identical way except for the absence of transglutaminase. To our knowledge, this is the first demonstration that transglutaminase catalyzes the incorporation of amines into a phospholipase, and that this post-translational modification increases phospholipase A2 activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096844     DOI: 10.1093/oxfordjournals.jbchem.a124021

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  16 in total

Review 1.  New weapons against inflammation: dual inhibitors of phospholipase A2 and transglutaminase.

Authors:  Lucio Miele
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 2.  Roles of transglutaminases in cardiac and vascular diseases.

Authors:  David C Sane; Jimmy L Kontos; Charles S Greenberg
Journal:  Front Biosci       Date:  2007-01-01

3.  Increased levels of gamma-glutamylamines in Huntington disease CSF.

Authors:  Thomas M Jeitner; Wayne R Matson; John E Folk; John P Blass; Arthur J L Cooper
Journal:  J Neurochem       Date:  2008-07-01       Impact factor: 5.372

Review 4.  Transglutaminase is a therapeutic target for oxidative stress, excitotoxicity and stroke: a new epigenetic kid on the CNS block.

Authors:  Manuela Basso; Rajiv R Ratan
Journal:  J Cereb Blood Flow Metab       Date:  2013-04-10       Impact factor: 6.200

5.  Transglutaminase 2 inhibits Rb binding of human papillomavirus E7 by incorporating polyamine.

Authors:  Ju-Hong Jeon; Kyung-Ho Choi; Sung-Yup Cho; Chai-Wan Kim; Dong-Myung Shin; Joon-Cheol Kwon; Kye-Yong Song; Sang-Chul Park; In-Gyu Kim
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

Review 6.  Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.

Authors:  William Bains
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

Review 7.  Transglutaminases and neurodegeneration.

Authors:  Thomas M Jeitner; John T Pinto; Boris F Krasnikov; Mark Horswill; Arthur J L Cooper
Journal:  J Neurochem       Date:  2009-05       Impact factor: 5.372

Review 8.  Prospects for the pharmacotherapy of amyotrophic lateral sclerosis : old strategies and new paradigms for the third millennium.

Authors:  Barry W Festoff; Zhiming Suo; Bruce A Citron
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

9.  Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

Authors:  Joonhong Sohn; Tae-Im Kim; Young-Hee Yoon; Joo-Yong Kim; Soo-Youl Kim
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

10.  PLA2G5 regulates transglutaminase activity of human IL-4-activated M2 macrophages through PGE2 generation.

Authors:  Munehiro Yamaguchi; Jennifer Zacharia; Tanya M Laidlaw; Barbara Balestrieri
Journal:  J Leukoc Biol       Date:  2016-03-02       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.